AIM
INO icon

Acrospire Investment Management’s Inovio Pharmaceuticals INO Stock Holding History

Acrospire Investment Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-434
Closed -$49K – 2314
2016
Q3 		$49K Sell
434
-575
-57% -$63.5K 0.03% 1082
2016
Q2 		$112K Buy
1,009
+490
+94% +$59.5K 0.08% 354
2016
Q1 		$54K Buy
+519
New +$40.1K 0.04% 872

Other funds holding INO

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Acrospire Investment Management's INO Position: Q4 2016 in Review

Acrospire Investment Management sold out of Inovio Pharmaceuticals (INO) in Q4 2016, closing a stake of 434 shares — an estimated $49K sold.

Acrospire Investment Management first reported a position in INO in Q1 2016 and held it in 3 quarters. The position peaked at $112K in Q2 2016. 125 funds tracked by Wall St. Rank hold INO as of Q4 2016.

  • Acrospire Investment Management reported no remaining Inovio Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Acrospire Investment Management sold 434 Inovio Pharmaceuticals shares in Q4 2016, an estimated $49K.
  • Acrospire Investment Management first reported a position in Inovio Pharmaceuticals in Q1 2016 and held it in 3 quarters.
  • Acrospire Investment Management's Inovio Pharmaceuticals position peaked at $112K in Q2 2016.
  • 125 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2016.

Based on Acrospire Investment Management's 13F filing for Q4 2016, filed 14 Feb 2017.